Patents by Inventor Martino Bolognesi

Martino Bolognesi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Avermectins and milbemycins for the treatment, prevention or amelioration of flavivirus infections
    Patent number: 8741856
    Abstract: Avermectin and milbemycin compounds, particularly the substance ivermectin, for preparing an antiviral medicament for the treatment, prevention or amelioration of a Flavivirus infection, such as those caused by YFV (yellow fever virus), DENV (Dengue virus), JEV (Japanese encephalitis virus), TBEV (tick-borne encephalitis virus) or MODV (Modoc virus) are provided. The antiviral compositions of the present invention are suitable for oral administration to a Flavivirus-infected subject or a subject at risk of a infection, such as a human or other mammal.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: June 3, 2014
    Assignees: Consiglio Nazionale Delle Ricerche, Aix-Marseille Universite', Katholieke Universiteit Leuven-K.U. Leuven R&D
    Inventors: Mario Milani De Mayo De Mari, Eloise Mastrangelo, Martino Bolognesi, Xavier De Lamballerie, Boris Pastorino, Johan Neyts, Suzanne Kaptein
  • SMAC mimetic compounds as apoptosis inducers
    Patent number: 8609685
    Abstract: The present invention relates to compounds conformationally constrained mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: December 17, 2013
    Assignee: CISI SCRL
    Inventors: Carlo Scolastico, Leonardo Pierpaolo Manzoni, Pierfausto Seneci, Laura Belvisi, Domenico Delia, Martino Bolognesi, Eloise Mastrangelo, Mario De Mayo De Mari Milani, Ilaria Motto, Carmelo Drago
  • AVERMECTINS AND MILBEMYCINS FOR THE TREATMENT, PREVENTION OR AMELIORATION OF FLAVIVIRUS INFECTIONS
    Publication number: 20120208778
    Abstract: Avermectin and milbemycin compounds, particularly the substance ivermectin, for preparing an antiviral medicament for the treatment, prevention or amelioration of a Flavivirus infection, such as those caused by YFV (yellow fever virus), DENV (Dengue virus), JEV (Japanese encephalitis virus), TBEV (tick-borne encephalitis virus) or MODV (Modoc virus) are provided. The antiviral compositions of the present invention are suitable for oral administration to a Flavivirus-infected subject or a subject at risk of a Flavivirus infection, such as a human or other mammal.
    Type: Application
    Filed: October 21, 2010
    Publication date: August 16, 2012
    Applicants: Consiglio Nazionale Delle Richerche, Katholieke Universiteit Leuven - K.U. Leuven R&D, Aix-Marseille Universite
    Inventors: Mario Milani De Mayo De Mari, Eloise Mastrangelo, Martino Bolognesi, Xavier De Lamballerie, Boris Pastorino, Johan Neyts, Suzanne Kaptein
  • SMAC MIMETIC COMPOUNDS AS APOPTOSIS INDUCERS
    Publication number: 20100267692
    Abstract: The present invention relates to compounds conformationally constrained mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.
    Type: Application
    Filed: November 5, 2008
    Publication date: October 21, 2010
    Inventors: Carlo Scolastico, Leonardo Pierpaolo Manzoni, Pierfausto Seneci, Laura Belvisi, Domenico Delia, Martino Bolognesi, Eloise Mastrangelo, Mario Milani, Ilaria Motto, Carmelo Drago
  • Structure-based hepatitis C virus drug design
    Patent number: 7657385
    Abstract: The extracellular loop of CD81 is a cellular receptor for the E2 protein of hepatitis C virus. A CD81 crystal structure has been elucidated and is provided for use in the structure-based design of compounds which bind to CD81 and thus block the binding of HCV. Methods such as docking and de novodrug design can be used.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: February 2, 2010
    Assignee: Novartis Vaccines and Diagnostics, S.R.L.
    Inventors: Martino Bolognesi, Guido Grandi
  • Modulation of tetraspanin function
    Patent number: 7252958
    Abstract: Tetraspanins have been found to dimerise. Methods for inhibiting or promoting the dimerisation of tetraspanins are provided, which may involve protein engineering of the tetraspanins themselves, or may rely on other molecules.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: August 7, 2007
    Assignee: Novartis Vaccines and Diagnostics S.R.L.
    Inventors: Martino Bolognesi, Guido Grandi
  • Modulation of tetraspanin function
    Publication number: 20040023297
    Abstract: Tetraspanins have been found to dimerise. Methods for inhibiting or promoting the dimerisation of tetraspanins are provided, which may involve protein engineering of the tetraspanins themselves, or may rely on other molecules.
    Type: Application
    Filed: May 1, 2003
    Publication date: February 5, 2004
    Inventors: Martino Bolognesi, Guido Grandi
  • Structure-based hepatitis c virus drug design
    Publication number: 20030176662
    Abstract: The extracellular loop of CD81 is a cellular receptor for the E2 protein of hepatitis C virus. A CD81 crystal structure has been elucidated and is provided for use in the structure-based design of compounds which bind to CD81 and thus block the binding of HCV. Methods such as docking and de novodrug design can be used.
    Type: Application
    Filed: April 22, 2003
    Publication date: September 18, 2003
    Inventors: Martino Bolognesi, Guido Grandi